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The experiments explored the extent to which alterations in L-type Ca2+ channel-mediated
Ca2+ entry triggers Ca2+-mediated arrhythmogenesis in Langendorff-perfused murine hearts
throughuseofthespeciﬁcL-typeCa2+channelmodulatorFPL-64716(FPL).IntroductionofFPL
(1μm) resulted in a gradual development (>10min) of diastolic electrical events and alternans
in spontaneously beating hearts from which monophasic action potentials were recorded.
In regularly paced hearts, they additionally led to non-sustained and sustained ventricular
tachycardia(nsVTandsVT).Programmedelectricalstimulation(PES)resultedinnsVTandsVT
after 5–10 and >10min perfusion, respectively. Pretreatments with nifedipine, diltiazem and
cyclopiazonic acid abolished arrhythmogenic tendency induced by subsequent introduction of
FPL,consistentwithitsdependenceuponbothextracellularCa2+entryandthedegreeofﬁllingof
thesarcoplasmicreticularCa2+ store.Valuesforactionpotentialdurationat90%repolarization
when any of these agents were applied to FPL-treated hearts became indistinguishable from
those shown by untreated control hearts, in contrast to earlier reports of their altering in
long QT syndrome type 3 and hypokalaemic murine models for re-entrant arrhythmogenesis.
These arrhythmic effects instead correlated with alterations in Ca2+ homeostasis at the
single-cell level found in investigations of the effects of both FPL and the same agents in
regularly stimulated ﬂuo−3 loaded myocytes. These ﬁndings are compatible with a prolonged
extracellular Ca2+ entry that potentially results in an intracellular Ca2+ overload and produces
the cardiac arrhythmogenecity following addition of FPL.
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The cardiac action potential (AP) in ventricular myocytes
is initiated by extracellular Na+ entry but subsequently
involves Ca2+ entry, mainly through L-type voltage-
dependent Ca2+ channels (LTCCs), that both maintains
thecelldepolarizationandinitiatesexcitation–contraction
coupling. The latter process requires a Ca2+-induced
Ca2+ release (CICR) through sarcoplasmic reticular
(SR) ryanodine receptor (RyR2) Ca2+ release channels
(Wehrens & Marks, 2003; Jiang et al. 2004; Scoote &
Williams, 2004). The consequent rise in cytosolic [Ca2+]
activates systolic cardiac muscle contraction. During
diastole, the extra Ca2+ is removed from the cytoplasm
through SR Ca2+-ATPase (SERCA2a) into the SR or
extruded from the cell via the Na+–Ca2+ exchanger
(NCX; Williams et al. 2001). Abnormalities in the Ca2+
homeostatic process have been implicated in triggered
arrhythmias, such as those associated with the ventricular
arrhythmogenesis leading to sudden cardiac death,
particularly in cardiac failure and catecholaminergic
polymorphicventriculartachycardia(Pogwizdetal.2001;
Williams et al. 2001; Jiang et al. 2002; Wehrens &
Marks, 2003; Balasubramaniam et al. 2005;Goddardet al.
2008). These arrhythmias may manifest as early after-
depolarizations (EADs), delayed after-depolarizations
(DADs) and action potential alternans.
The present experiments, performed in both whole
hearts and single myocytes, explore the extent to which
alterations in LTCC-mediated entry of Ca2+ might
eventually trigger mechanisms of this kind, through the
useofthespeciﬁcL-typecalciumchannelmodulatorFPL-
64716 (FPL; Baxter et al. 1993; Triggle 2004). FPL appears
to prolong both the opening of L-type Ca2+ channels
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during depolarization and the time course of inactivation
uponrepolarization(Rampe&Lacerda,1991;Zhengetal.
1991; Kunze & Rampe, 1992; Lauven et al. 1999; Fan
et al. 2000). Patch clamp studies from rat ventricular
myocytes showed that FPL increased the amplitude of
both Ca2+ currents and Ca2+ transients more than it
increased the rate of rise of Ca2+ t r a n s i e n t s .I ta l s os l o w e d
activation and inactivation, and enhanced the duration of
tail currents upon repolarization (Fan & Palade, 2002).
Our ﬁndings indeed demonstrate such arrhythmogenic
effects of FPL, attributable to an enhanced Ca2+ entry,
probably accompanied by consequent alterations in SR
Ca2+ store.
Methods
Animals
Mice bred against a 129 genetic background (Harlan
UK Ltd, Bicester, UK), housed at room temperature, fed
sterile rodent chow with free access to water at all times
and subjected to 12h–12h light–dark cycles were studied
at ages between 5 and 10months. They were killed by
cervical dislocation (Schedule1, UK Animals (Scientiﬁc
Procedures) Act 1986).
Experiments on Langendorff-perfused hearts
Hearts were dissected out and immediately immersed
into ice-cold bicarbonate-buffered Krebs–Henseleit (KH)
buffer (containing, in mmoll−1): NaCl,119; Na2CO3,25;
KCl,4; KH2PO4,1.2; MgCl2,1.0; CaCl2,1.8; glucose,
11; and sodium pyruvate,2.0. The buffer was made
daily and equilibrated with a 95% O2–5% CO2 gas
mixture (British Oxygen Company, Manchester, UK)
(Bethelletal.1998).Theelectrophysiologicalexperiments
on arrhythmogenesis at the whole heart level used a
Langendorff-perfusedpreparationadaptedforthemurine
model (Papadatos et al. 2002; Balasubramaniam et al.
2003). The perfusate was passed through a water-jacket
at a ﬂow rate of 2.0–2.5mlmin−1 (model 505s, Watson-
Marlow Berdel, Falmouth, UK). Fluid in the water-jacket
was circulated with a circulator (model C−85A, Techne,
Cambridge, UK) and warmed to 37◦C by passing through
a water-bath. The perfusate was then passed through 200
and 5μm ﬁlters (Millipore, Watford, UK) before passing
into the aorta of the heart. Hearts were thus perfused
using buffer in which catecholamines were absent. They
were then allowed to beat spontaneously until a steady
state was reached, a time that permitted ample time for
washoutofanycatecholaminesthatmayhavebeenpresent
in the circulation at the time of killing.
The contracting heart was stimulated with a custom-
made platinum stimulating electrode applied to the
epicardial surface, usually for 15min at 10Hz, and was
allowed to reach a physiologically steady state. The heart
was paced from its right ventricle at three times its
threshold level (between 3 and 5V) using square-wave
stimuli of 2ms duration (Grass S48 stimulator, Grass
Telefactor, Slough, UK). Monophasic action potentials
(MAPs) were recorded from the epicardial basal surface
of the left ventricle using a contact-type MAP electrode
(Linton Instruments, Harvard Apparatus, Edenbridge,
UK).
Following the equilibration period, hearts were ﬁrst
studied in conditions of spontaneous activity, which
typicallytookplaceataheartrateof∼6Hz.Theywer ethen
subjectedtoconstantventricularpacingatcyclelengthsof
8 and 10Hz. Finally, they were subjected to programmed
electrical stimulation (PES) using a variation of existing
clinical techniques (Saumarez & Grace, 2000; Saumarez
et al. 2003). The stimulation sequence consisted of a
drive train of pacing stimuli (S1) applied with a 200ms
cycle length, with an extra stimulus (S2) inserted every
eighth beat performed at cycle lengths of 8 and 10Hz
for determination of the ventricular effective refractory
period (VERP).
The MAP signals were ampliﬁed, ﬁltered (band-pass
ﬁlter 0.5Hz to 1kHz, Gould-Nicolet Technologies, Ilford,
UK) and digitized at a frequency of 5kHz using an
analog-to-digital converter (model 1401plus, Cambridge
ElectronicDesign,Cambridge,UK).MonophasicAPsthat
were considered for analysis were all stable for more than
30min,andthedataweremanuallyreviewedusingSpike2
software (CED, Cambridge, UK). According to accepted
criteria regarding MAP morphology, MAP traces selected
shouldhaveastablebaselinewitharapidupstrokewithout
inﬂectionornegativespikes,consistentamplitude>1mV ,
and rapid ﬁrst phase repolarization lacking an early
plateau. Action potential duration (APD) was analysed at
30, 50, 70 and 90% repolarization (APD30, APD50,A P D 70
and APD90) following previous MAP analysis protocols
(Gussak & Antzelevitch, 2000; Fabritz et al. 2003). Results
are all expressed as means± S.E.M.
Pharmacological agents studied were all purchased
fromSigma-Aldrich,Poole,UK.TheCa2+ channelagonist
FPL-64716 (FPL) was initially made up with dimethyl
sulphoxide (DMSO) to make a stock concentration of
5m M. Stock solutions of FPL were wrapped in foil
because they are photosensitive and stored at −20◦C.
Cyclopiazonicacid(CPA)wasdissolvedin96%ethanolto
make an initial stock solution of 10mM, which was stored
at −20◦C. Diltiazem was dissolved in distilled water to
make a stock concentration of 1mM and kept refrigerated
at 4◦C. Final drug solutions used were diluted with KH
buffer made fresh before every experiment. The FPL was
diluted to a working concentration of 1μM.T h eC P Aw a s
diluted to an intermediary solution of 10μM and then
further diluted to a concentration of 150nM. Nifedipine
and diltiazem were both used at a ﬁnal concentration of
100nM.
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Arrhythmogenic phenotypes in the form of after-
depolarizations, delayed after-depolarizations, alternans,
and monomorphic and polymorphic ventricular
tachycardia were examined both before and following
introduction of FPL in both control conditions
and following subsequent additions of nifedipine,
diltiazem and CPA. After-depolarizations were deﬁned
as depolarizing electrical events that interrupted the
restitutionphasesofactionpotentials,whereaspremature
activations took place following full action potential
recovery. Spontaneous tachycardias prolonged over more
than 30s were deﬁned as sustained, whereas those lasting
less than 30s were deﬁned as non-sustained.
Statistical analysis of results obtained in the different
pharmacological conditions was carried out using
either paired or unpaired two-way ANOVA (SPSS Inc.,
Chicago, IL, USA) for continuous data and Fisher’s
exact test for categorical data. Results are all expressed
as means± S.E.M., and differences were considered
signiﬁcant at a level of P <0.05.
Measurements of myocyte [Ca2+]
Single-cell experiments used mouse ventricular myocytes
isolated by adapting an established enzymatic digestion
described previously (Harding et al. 1992). Following
killing, hearts were excised rapidly and cannulated
before being connected to a Langendorff perfusion
system. The heart was then perfused for 1.5min at
3mlmin −1 with perfusion buffer containing (mM):
NaCl,120; MgSO4,5 ;K C l , 5 . 4 ;s o d i u mp y r u v a t e , 5 ;
Hepes,10; glucose,5; taurine,20; nitrilotriacetic acid
(NTA),5 (Sigma-Aldrich); and adjusted using NaOH to
pH7.0 at 37◦C. Subsequently, the heart was perfused for
25–28min at 3mlmin−1 with digestion buffer containing
(mM): NaCl,120; MgSO4,5 ;K C l ,5 . 4 ;s o d i u mp yr u v a t e ,5 ;
Hepes,10; glucose,5; and taurine,20, to which was added
collagenase typeII (Worthington, Lakewood, NJ, USA;
ﬁnal concentration 1mgml−1), hyaluronidase (Sigma-
Aldrich; ﬁnal concentration 1mgml−1) and 200μM Ca2+
and adjusted using NaOH to pH6.8 at a temperature of
37◦C .T h ep a l ea n ds w o l l e nh e a r tw a st h e nr e m o v e da n d
cut below the atria. The digested tissue was teased gently
withﬁneforceps,andthedissociatedcellsweretransferred
to a conical tube containing 12.5ml digestion buffer
with 50mg bovine serum albumin (BSA) to inactivate
digestion. The resulting myocytes were subjected to
further trituration using sterile plastic transfer pipettes,
and allowed to sediment by gravity for 10min.
The cell suspension was then centrifuged for 1.5min
at 100 g and the pellets resuspended twice in wash
buffercontaining(mM):NaCl,119;KCl,4.2;MgSO4,0.94;
KH2PO4,1.2; Hepes,20; glucose,11.5; taurine,20; and
1mgml −1 BSA, and bubbled with 95% O2–5% CO2,
pH7.4, to remove all traces of NTA, collagenase and
hyaluronidase. Calcium chloride was then cautiously
reintroduced by stepwise (0.2 mM) additions to reach an
approximate concentration of 1.25mM, by centrifuging
the preparation at each Ca2+ reloading stage to remove
dead or swollen cells. During this process, myocytes
were examined periodically under the microscope
to conﬁrm a good yield of rod-shaped myocytes
(better than 60%) before continuing the experiments.
Cells were then transferred into a conical tube (BD
Biosciences, Oxford, UK) and incubated at room
temperature. The isolated myocytes were then placed in
a control Hepes-buffered Krebs–Henseleit solution that
was the same as the wash buffer mentioned previously
without BSA and had a pH of 7.2, and transferred
to a Perspex chamber 10mm×4mm×6.25mm
(length×width×depth). The myocytes spontaneously
attached to the glass coverslip (3cm×3cm, grade1
coverslip (Merck, Hoddesdon, Herts, UK) forming the
ﬂoor of the chamber. The myocytes were stimulated
to contract using two in-built platinum ﬁeld electrodes
running the length of the chamber through which the
periodicﬁeldstimulationwasappliedusingacustom-built
square-wave stimulator. This applied successive 40–60V
steps of duration 2.2ms, immediately followed by a step
of similar duration and amplitude but opposite polarity
at a pacing frequency of 0.5Hz. During this stimulation,
cells were loaded with the acetoxymethyl (AM) ester of
ﬂ u o - 3( I n vi tr o g e n ,P a i s l ey ,U K ;5 0μg vial diluted in 30μl
pluronicacidtogiveastockconcentrationof1.476mM)by
incubating the cells in a bath of volume 500μl containing
KH buffer (with 1.25mM Ca2+) with 2μlo fﬂ u o −3AM
solution for 15min at room temperature in the dark. The
bathwiththemyocyteswasthentransferredontothestage
of a Zeiss LSM-510 laser scanning confocal microscope
system (Carl Zeiss Ltd, Welwyn Garden City, UK) with a
×20 air objective (NA0.5; confocal aperture 1000μm,
slice thickness <42.4μm) on a Zeiss Axiovert100M
inverted microscope. Fluo−3 ﬂuorescence emission was
excited with a 488nm argon laser and measured at
505–550nM. Images were analysed using an in-house
custom-written program. A series of 500frames sampled
at 98ms per frame (128×128pixels per frame) were
used initially to monitor ﬂuorescence changes over time.
The appropriateness of the chosen frame capture rate
was corroborated in some experiments by collecting data
in the faster line-scan mode with a sampling rate of
960μs per line. All traces had stable baselines, conﬁrming
consistent laser intensities and detector gains. The peak
normalized ﬂuorescence (F/F0) values following each
response to each stimulus were calculated for each time
series, and a mean was acquired for each series. Moreover,
the mean peak F/F0 values as well as the baseline diastolic
values were calculated. The results are expressed as mean
values± S.E.M. and compared using ANOVA (SPSS Inc.).
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Different solutions were perfused through the perfusion
chamberasrequired.Allconfocalmicroscopestudieswere
c a r r i e do u ta tr o o mt e m p e r a t u r e .
Results
Recordings of MAPs demonstrate arrhythmic
effects of FPL
PreviousworkhasdemonstratedthatFPL(1μM)increases
extracellular Ca2+ entry through L-type Ca2+ channels,
thereby enhancing cytosolic Ca2+ loading (Fan & Palade,
2002). It therefore served as a useful pharmacological tool
to assess the effect of the resulting alterations of cellular
Ca2+ homeostasis on cardiac arrhythmogenic properties.
Such experiments ﬁrst compared MAP waveforms
from epicardial surfaces of the left ventricles of eight
Langendorff-perfused hearts during both spontaneous
activity (Fig.1A) and during regular pacing at 8Hz
(Fig.1B) before and at different times following the
introduction of FPL (1μM) into the perfusing KH buffer
solution.Thetracesshownineachpanelexemplifyresults
from ∼2min of recordings in each condition. Before
introduction of FPL all hearts showed normal MAP
waveforms whose time courses resembled those reported
on earlier occasions (Fabritz et al. 2003; Killeen et al.
Figure 1. Examples of monophasic action waveforms
Epicardial monophasic action waveforms from epicardial surfaces of the left ventricles of Langendorff-perfused
hearts during both non-paced activity (A) and regular pacing at 8 Hz (B)b e f o r e( a) and at different times following
the introduction of 1 μM FPL-64716 (FPL) into the perfusing KH buffer solution (b–d).
2007a) and no evidence of arrhythmogenic behaviour
(Fig.1Aa and Ba).
Figure2 summarizes numbers of hearts showing each
phenomenon, as well as the results of Fisher exact tests
for these incidences when compared with control values
obtained in the absence of FPL. Introduction of FPL then
led to a progressive development, over 0–10min, of a
varietyofwaveformabnormalitiesinbothnon-pacedand
pacedhearts(Figs1Ab–d andBb–d and2Ab–d andBb–d).
Duringspontaneousactivity,1minofexposuretoFPLleft
MAPwaveformsandrhythmrelativelynormalapartfrom
a single episode of 40pairs of action potentials showing a
stable interval alternans, attributable to either ventricular
orsupraventricularchanges,inasingleheart(Figs1Aband
2Ab).Atbetween5–10minofFPLperfusion,asingleheart
showed120pairsofactionpotentialsinalternans(Figs1Ac
and 2Ac). At >10min following introduction of FPL, two
hearts showed 12 and 50pairs of APs in alternans, and
MAPsinthreeheartsshowedrepetitivespikesinterrupting
the time courses of the AP recoveries (Fig.1Ad), resulting
in a statistically signiﬁcant (P =0.009) incidence of
arrhythmiceventscomparedwithcontrolresultsobserved
before addition of FPL (Fig.2Ad).
In paced hearts, with 1min of exposure to FPL there
were no arrhythmic episodes (Fig.1Bb)a p a r tf r o ma
single 40s episode of stable alternans and one DAD
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in one heart (Fig.2Bb). A total of four hearts perfused
for 5–10min with FPL exhibited episodes of alternans
with a mean duration of 25±7.6s (P =0.07, compared
with control); of these, two hearts showed EADs that
intercepted the recovery phase of approximately two and
sixoutof20successiveAPs.Moreover,fourheartsshowed
DADs, giving an overall statistically signiﬁcant incidence
of arrhythmic phenomena (P =0.006) compared with
control hearts (Figs 1Bc and 2Bc). With >10min
exposure to FPL, three hearts showed ﬁve episodes of
stable alternans of mean duration 21±6.4s. In addition,
three hearts showed EADs that interrupted six, 10 and
three out of 20 successive action potentials, three hearts
showed DADs, two hearts showed episodes of ventricular
tachycardia (VT) lasting <30s, and six hearts showed
episodes of VT lasting >30s (Figs1Bd and 2Bd). The
incidenceofsustainedVT(sVT)andtheoverallincidence
of arrhythmic events were both signiﬁcantly higher
(P =0.006, P =0.0001) than corresponding incidences
obtained before addition of FPL.
Figure 2. Arrhythmic phenomena in non-paced and paced hearts
Numbers of hearts showing arrhythmic phenomena out of a total of n = 8 studied during both non-paced activity
(A) and regular pacing at 8 Hz (B)b e f o r e( a) and at different times following the introduction of 1 μM FPL-64716
(FPL) into the perfusing KH buffer solution (b–d). The bar graphs show incidences of hearts having one or more
episodes of alternans (Ab–Ad and Bb–Bd), early and delayed after-depolarizations (EADs and DADs; Ad, Bc and
Bd) or episodes of ventricular tachycardia (VT; Bd). The bar graphs also show results of Fisher’s exact tests for
these incidences when compared with control values obtained in the absence of FPL (∗P < 0.01, ∗∗P < 0.001 and
∗∗∗P < 0.0001; open bars indicate and absence or insigniﬁcant incidence of the arrhythmic phenomenon).
Programmed electrical stimulation procedures then
provided quantiﬁable tests for arrhythmic substrate as
employedonpreviousexperimentalandclinicaloccasions
(Saumarez & Grace, 2000; Balasubramaniam et al.
2003). Figure3 illustrates ﬁndings showing that FPL
treatment resulted in signiﬁcant arrhythmic substrate.
Thus: (1)regularly paced untreated hearts showed no
arrhythmic incidents (n=8; Fig.3A); (2)seven out of
eight hearts perfused with FPL for 5–10min showed non-
sustained VT (nsVT), representing a signiﬁcant increase
in such arrhythmic incidence (Fig.3B; Fisher exact test
g i v i n gat w o - t a i l e dp r o b a b i l i t yo fP <0.001); and (3)all
eightheartsshowedepisodesofsVTwithfurtherperfusion
with FPL for more than 10min (Fig.3C; P <0.0001).
Pharmacological modiﬁcations of the effects of FPL
We next explored the effects of pretreatments with
the dihydropyridine Ca2+ channel blocker nifedipine
(100nM), the benzothiazepine Ca2+ blocker diltiazem
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(100nM) and the effects of the SERCA inhibitor CPA
(150nM) before restoring FPL to the buffer, in both
regularly paced hearts (Fig.4A) and in hearts undergoing
PES (Fig.4B). Cyclopiazonic acid (Goeger et al. 1988;
Mason et al. 1989; Seidler et al. 1989) speciﬁcally inhibits
SERCA activity in myocardial vesicle preparations by
∼50%at100–200nMandcompletelyat10μM(Schwinger
etal.1997)whilstsparingCa2+sensitivityinthecontractile
myoﬁlaments (Takahashi et al. 1995), Ca2+ currents
(Bonnet et al. 1994) and NCX activity (Yard et al. 1994).
None of the hearts on pretreatment with nifedipine
(n=4hearts;Fig.4Aa and Ba), diltiazem (n=4h e a r t s ;
Fig.4Ac and Bc)o rC P A( n=4; Fig.4Ae and Be)s h o w e d
arrhythmic phenomena. Inclusion of either nifedipine
or diltiazem during subsequent FPL treatment totally
suppressed FPL-induced VT (Fig.4Ab, Ad, Bb and Bd)
through either pacing protocol in the same hearts.
Treatment with CPA in combination with a subsequent
addition of FPL (Fig.4Af and Bf ) abolished FPL-induced
VT, although it did permit EAD episodes following the
shortest S2 stimuli in all four hearts (Fisher’s exact test,
P=0.002 when tested against results with FPL alone in
each case).
Correlations between arrhythmic actions
and AP waveform
Exposure to FPL thus produced VT in isolated murine
hearts, and this occurred along with phenomena
associated with triggered arrhythmogenesis such as EADs
and alternans.The experimentsthat followedinvestigated
the extent to which FPL produces changes in APD and
Figure 3. Monophasic action potentials
recorded from the epicardium of hearts in
the absence and presence of FPL
Monophasic action potentials recorded from
the epicardium of hearts before (A), 5–10 min
(B)a n d>10 min after the addition of 1 μM FPL
(C). All experiments were performed during PES
at 8 Hz; the arrows indicate S2 extra-stimuli.
The examples illustrated that before addition of
FPL (A), isolated perfused hearts showed a
persistently regular rhythm with no
arrhythmogenic events during the PES
procedures. The S2 extra-stimuli initiated an
episode of nsVT lasting for less than 30 s in 7
out of 8 hearts perfused with FPL for 5–10 min
(B). All 8 hearts showed episodes of sVT lasting
for more than 30 s with further perfusion with
FPL for more than 10 min (C).
refractory period, since alterations in these have been
observed in previous long QT syndrome (LQTS) and
hypokalaemic murine cardiac models and have been
implicatedinthere-entrantsubstrateresponsiblefortheir
abnormalelectricalactivity(Stokoeetal.2007a,b;Thomas
et al. 2007b). Both mechanisms could co-exist. Timothy
syndrome,attributedtoabnormalitiesintheLTCC,results
in a multisystemdisorderthatalsocausesLQTS(Splawski
et al. 2004, 2005).
Firstly, epicardial APD values were accordingly
measured at x =30, 50, 70 and 90% recovery (APD30,
APD50,A P D 70 and APD90) from left ventricular MAPs
obtained from hearts paced at 8Hz (Table 1). In
control hearts, APD90 was 48±3.5ms (n=6hearts),
in agreement with previous reports (e.g. Killeen et al.
2007b). We then investigated the effects of FPL (1μM;
n=6hearts), at different perfusion times (0–1, 5–10 and
>10min) identical to those adopted above upon values
of APDx. Application of two-way ANOVA to each of the
above groups demonstrated that there were no signiﬁcant
differences between treated or untreated groups with the
exception of APD30 values obtained between 5–10min.
Therefore, FPL did not signiﬁcantly alter action potential
time course despite the occurrence of EADs and alternans
but not sVT at times <10min and the appearance of
all three phenomena at times >10min. This progressive
development of arrhythmogenesis is therefore more likely
to arise from progressive increases in intracellular Ca2+
resulting from increased net Ca2+ inﬂux brought about
by FPL. The ﬁndings complement recent reports in a
murine RyR2 model whose arrhythmogenic properties
were attributable to alterations in RyR2 (Goddard et al.
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Table 1. Left ventricular epicardial action potential durations at different repolarization times in regularly paced (8 Hz)
hearts at different perfusion times in the presence and absence of 1 μM FPL-64716
APD30 (ms) APD50 (ms) APD70 (ms) APD90 (ms)
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M.
KH buffer (n = 6) 6 1.0 14 1.3 27 3.0 48 3.5
0–1 min KH buffer (n = 6) 6 1.4 13 3.1 24 4.0 47 3.0
5–10 min KH buffer (n = 6) 4 0.5 14 1.5 29 3.6 54 2.3
>10 min KH buffer (n = 6) 6 0.6 13 2.8 27 3.6 54 1.5
KH buffer (n = 6) 11 0.1 18 0.1 26 0.2 43 0.2
0–1 min 1 μM FPL (n = 6) 10 1.3 20 1.5 31 1.7 49 1.2
5–10 min 1 μM FPL (n = 6) 13 4.1 22 5.0 33 4.2 53 1.5
>10 min 1 μM FPL (n = 6) 6 2.2 11 4.2 22 4.5 60 2.8
n gives number of hearts.
2008). They contrast with re-entrant arrhythmogenic
propertiesassociatedwithalteredactionpotentialkinetics
demonstrated in models for long QT syndrome type 3
(LQT3) (Thomas et al. 2007a).
Secondly, we followed APD90 values for successive
alternate MAPs during episodes of alternans in paced
hearts. At 1, 5–10 and >10min following FPL
introduction, the mean duration of the shorter of
Figure 4. Epicardial monophasic action potential recordings in paced hearts and in hearts undergoing
PES in the presence of various drugs
Epicardial MAP recordings obtained from both regularly paced hearts (A) and hearts undergoing PES (B) pretreated
with 100 nM nifedipine (a), 100 nM diltiazem (c) and 150 nM CPA (e) before restoring 1 μM FPL to the buffer. None
of the hearts showed arrhythmic phenomena following pretreatment (a, c and e). Inclusion of either nifedipine
or diltiazem during subsequent FPL treatment totally suppressed FPL-induced VT (b and d, respectively) through
either pacing protocol. However, 150 nM CPA in combination with a subsequent addition of 1 μM FPL (f) abolished
FPL-induced VT although it did permit EAD episodes following the shortest S2 stimuli in each of n = 4 hearts.
each pair of MAPs was 31±1.5 (n=1heart, 20action
potentials), 30±1.5 (n=4hearts, 20action potentials)
and 35±1.8ms (n=3hearts); the corresponding value
for the longer of each pair was 45±0.7 (n=1heart),
46±0.3 (n=4hearts) and 65±2.1ms (n=3hearts),
respectively (Fig. 5).
Thirdly, neither pretreatment with nifedipine
(n=6hearts), diltiazem (n=5hearts) and CP A
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Table 2. Effects of nifedipine, diltiazem and cyclopiazonic acid on action potential duration in the presence and absence of 1 μM
FPL-64716
APD30 (ms) APD50 (ms) APD70 (ms) APD90 (ms)
Mean S.E.M. Mean S.E.M. Mean S.E.M. Mean S.E.M.
KH buffer (n = 4) 10 2.0 19 3.1 30 3.2 49 1.7
100 nM nifedipine (n = 6) 6 1.7 19 1.8 30 1.6 49 1.4
100 nM nifedipine + 1 μM FPL (n = 8) 9 1.4 17 1.6 30 1.5 49 1.1
KH buffer (n = 5) 7 1.5 16 2.2 30 2.5 52 2.5
100 nM diltiazem (n = 5) 4 0.6 13 1.0 28 1.9 50 2.1
100 nM diltiazem + 1 μM FPL (n = 7) 6 0.6 16 1.5 30 1.5 53 0.9
KH buffer (n = 5) 11 1.5 20 1.5 30 1.4 47 1.4
150 nM CPA (n = 9) 13 1.6 20 2.3 30 2.9 49 3.2
150 nM CPA + 1 μM FPL (n = 7) 10 1.9 19 2.1 29 2.9 47 3.7
n gives number of hearts.
(n=9hearts) nor a further addition of FPL resulted in
any signiﬁcant change in APDx as indicated by ANOVA
(Table 2).
Calcium transients in single mouse myocytes
Theexperimentsthatfollowedcorrelatedthesearrhythmic
effects with changes in the amplitude and pattern of
Ca2+ transients measured in ﬂuo-3 loaded isolated
murine cardiac myocytes. These were subjected to regular
stimulation (0.5Hz), whose timing is indicated by the
dots below the F/F0 traces in Figs6–9. Cells were studied
in KH buffer under identical FPL concentrations, in the
presence and absence of pretreatments with nifedipine,
diltiazem and CPA. In all these experimental conditions,
F/F0 tracesshowedstablebaselinesandreproduciblepeak
responsestoregularstimulationwithminimalevidenceof
ﬂuorophor bleaching over the adopted sampling periods
as assessed by readings obtained at the beginning and end
o ft h ea d o p t e d ,5 0s ,s a m p l i n gp e r i o d s( P 5%).
Before addition of FPL, the Ca2+ signals observed
immediately following commencement of stimulation
consistedofseriesofresponseswithconsistentamplitudes,
each directly following the individual stimuli with a peak
F/F0 of 1.53±0.02 (events counted over a standard
sampling period of 50s; n=6cells; cells from at least
2hearts studied in each condition). The myocytes did not
show spontaneous ectopic peaks in the intervals between
stimuli,nordidtheyshowanysubsidiaryeventsduringthe
recovery phases of the evoked Ca2+ transients (Fig.6A).
In contrast, resumption of scanning within 15s
of addition of FPL demonstrated F/F0 transients
with increased amplitudes of 1.93±0.03 (n=3c ells,
P <0.001) that showed subsidiary events (1.64±0.03,
n=6c e l l s ,2h e a r t s ;F i g .6 B). The additional Ca2+ entry
from either the extracellular space or Ca2+ stores reﬂected
in such subsidiary events would lead to a progressive
cytosolicCa2+ loading,which,if the causeofthe observed
arrhythmogenesis, would account for the gradual onset
of the arrhythmic phenomena described here. However,
followingthisinitialscanning,withcontinuedstimulation
for >120s, resumption of scanning demonstrated F/F0
transientswhoseamplitudesweresigniﬁcantlylower(peak
F/F0 of 1.53±0.02, n=6c ells,2hearts,P <0.05) with
subsidiary events of amplitude 1.27±0.02 (n=3c ells;
Fig.6C and D), a ﬁnding compatible either with
photobleaching or a consequent depletion of the Ca2+
store.
The effects of the pharmacological agents nifedipine
(100nM; Fig. 7), diltiazem (100nM;F i g .8 )a n dC P A
(150nM; Fig. 9) were then compared before and
10min after a subsequent addition of FPL in similarly
stimulated cells. Despite their sharply differing sites of
actionininﬂuencingCa2+ homeostasis,suchmanoeuvres
yielded similar results. Thus, the addition of nifedipine,
diltiazem and CPA all reduced peak F/F0 in a similar
manner, signiﬁcantly (P <0.05; one-way ANOVA), from
2.11±0.04 (n=6cells), 1.77±0.02 (n=3c ells) and
3.20±0.04 (n=9c ells; Figs7A and D,8 A and D and
9A and D) to 1.37±0.02 (n=9cells), 1.30±0.01
Figure 5. The effect of alternans on APD90 values
The APD90 values in alternans were calculated for alternans that
appeared 1 min following introduction of FPL. However, the presence
of alternans signiﬁcantly (∗P < 0.001) decreased APD90 values with
increased FPL perfusion times after 1 min, 5–10 min and >10 min
perfusion with FPL.
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(n=3cells)and1.80±0.06(n=12cells)(Figs7BandD,
8BandDand9BandD),respectively.Theseﬁndingsagree
withearlierresultsthathadusedsimilarconcentrationsof
nifedipine and diltiazem (Balasubramaniam et al. 2004).
However, in all three cases, following washout and
reintroduction of solutions that also included 1μM FPL,
giving an overall sequence of solution changes identical
to that used in the corresponding experiments on whole
hearts, there was no further signiﬁcant change in values
of F/F0, which were left at 1.28±0.05 (n=6c ells),
1.31±0.01 (n=4cells) and 1.57±0.05 (n=6c ells;
Figs7C and D,8 C and D and 9C and D, respectively)
even after 1min following perfusion of the new agents.
Furthermore, the presence of nifedipine and diltiazem
abolished both ectopic and subsidiary Ca2+ release events
(Figs7C and D and 8C and D) in parallel with the similar
absenceofanyarrhythmicphenomenainthewholehearts.
In contrast, myocytes treated with both CPA and FPL
showed persistent spontaneous ectopic Ca2+ peaks in
the intervals between stimuli. There were also subsidiary
events whose peak F/F0 (1.32±0.02; n=6c ells) was
similar to those observed with FPL. Nevertheless they
occurred signiﬁcantly less frequently, in 5±0.20 out of
23 evoked transients (n=22cells, 4hearts; Fig.9C)t h a n
Figure 6. Fluo−3 ﬂuorescence measurements in isolated myocytes studied using confocal microscopy
Normalized ﬂuorescence (F/F0) plotted against time with myocyte exposed to periodic ﬁeld stimulation in perfusion
buffer alone prior to any pharmacological manoeuvre (A) and records obtained following addition of 1 μM FPL to
the buffer for approximately 15 s (B) and approximately 120 s (C). D shows overall mean peak F/F0 values taken
from the entire set of myocytes. The overall mean peak F/F0 values are represented for the entire set of myocytes
(Di) and subsidiary events (Dii).
in myocytes treated with FPL alone. These last ﬁndings
correlate with the persistence of transient arrhythmic
events observed in the whole hearts.
Discussion
The present experiments explored the extent to which
alterations in LTCC-mediated entry of Ca2+ might
eventually trigger Ca2+-mediated arrhythmogenesis in
isolated perfused murine hearts through use of the
speciﬁc L-type calcium channel modulator FPL-64716
(Baxter et al. 1993; Triggle, 2004). FPL is known to
increase the contractility of both smooth and cardiac
muscle (Zheng et al. 1991; Rampe & Dage, 1992; Rampe
et al. 1993). Murine hearts have already successfully been
used to replicate arrhythmogenic properties associated
with Brugada and LQT3 syndromes in which re-entrant
mechanisms have been implicated (Stokoe et al. 2007a,b;
Thomas et al. 2007a,b). Recently, murine models have
been used in studies of an arrhythmogenic condition
related to abnormal RyR2 function (Cerrone et al. 2005;
Goddard et al. 2008). Their use in the present study
permitted our examination not only of the physiological
effects of alterations in Ca2+ homeostasis on murine
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Figure 7. Calcium transients in regularly stimulated isolated myocytes in the presence of nifedipine and
FPL
Calcium transients in regularly stimulated (0.5 Hz) isolated myocytes before (A) and after addition of 100 nM
nifedipine (B) and a further addition of FPL (C). D, nifedipine signiﬁcantly (∗∗∗P < 0.05; one-way ANOVA) reduced
peak F/F0 from 2.11 ± 0.04 to 1.37 ± 0.02 (n = 9 cells), but there were no further changes following introduction
of FPL, which left a peak F/F0 of 1.28 ± 0.05 (n = 6 cells).
Figure 8. Calcium transients in regularly stimulated isolated myocytes in the presence of diltiazem and
FPL
Calcium transients in regularly stimulated (0.5 Hz) isolated myocytes before (A) and after addition of 100 nM
diltiazem (B) and a further addition of FPL (C). D, diltiazem signiﬁcantly (∗∗∗P < 0.05; one-way ANOVA) reduced
peak F/F0 from 1.77 ± 0.02 (n = 3 cells) to 1.30 ± 0.01 (n = 3 cells), but there were no further changes following
introduction of FPL, which left a peak F/F0 of 1.31 ± 0.01 (n = 4 cells).
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cardiac function, but also their comparison with these
previously described murine models.
Treatment with FPL resulted in a gradual development
of arrhythmogenic phenomena in an absence of marked
alterations in action potential waveform. This would be
unexpectedhadFPLactedasasimpleCa2+channelagonist
to increase inward Ca2+ current. However, FPL is likely to
havemorecomplexactionsinadditionallyslowingL-type
Ca2+ channel opening during depolarization and slowing
inactivationuponrepolarization(Rampe&Lacerda,1991;
Zheng et al. 1991; Kunze & Rampe, 1992; Lauven et al.
1999; Fan et al. 2000; Fan & Palade, 2002), features
that would compromise its full agonist action, and any
consequence upon subsequent NCX activity (see e.g.
Noble et al. 2007) in the situation of the relatively
brief, triangulated action potentials (Danik et al. 2002;
Hondeghem, 2007; Milberg et al. 2007) found in murine
systems.
In the Langendorff-perfused murine hearts,
introduction of FPL resulted in a gradual development
(over 10min) of diastolic electrical events and alternans
in non-paced hearts. In paced hearts, FPL led to an
additional appearance of arrhythmic, nsVT and sVT
phenomena. Finally, hearts were subjected to PES.
Figure 9. Calcium transients in regularly stimulated isolated myocytes in the presence of CPA and FPL
Calcium transients in regularly stimulated (0.5 Hz) isolated myocytes before (A) and after addition of 150 nM
CPA (B) and a further addition of FPL (C). D, CPA signiﬁcantly (∗∗∗P < 0.05; one-way ANOVA) reduced peak F/F0
from 3.20 ± 0.04 (n = 9 cells) to 1.80 ± 0.06 (n = 12 cells), but there were no further changes in peak F/F0
following introduction of FPL, which left a peak F/F0 of 1.57 ± 0.05 (n = 6 cells), but an appearance of persistent
spontaneous ectopic Ca2+ peaks in the intervals between stimuli whose peak F/F0 was 1.32 ± 0.02 (n = 6 cells;
C and D).
Results from this have been shown to correlate with
arrhythmogenic tendency in genetically modiﬁed hearts
modelling Brugada syndrome (Stokoe et al. 2007a),
LQT3 (Head et al. 2005; Stokoe et al. 2007b) and long
QT syndrome type 5 (LQT5) (Balasubramaniam et al.
2003; Thomas et al. 2007b) and to provide indications of
clinical arrhythmogenic risk (Saumarez & Grace, 2000;
Saumarez et al. 2003; Turner et al. 2005). In the present
experiments, this procedure resulted in nsVT and sVT
after 5–10 and >10min perfusion, respectively. However,
there were no accompanying alterations in APD when
values obtained at matched times were compared in the
presence and absence of FPL. This contrasts with the
increases in APD associated with re-entrant substrate in
other murine models (Killeen et al. 2007a).
In contrast, diastolic events of the kind observed
here have previously been attributed to a range of Ca2+
homeostatic events. Thus, EADs have been attributed to
L-type Ca2+ current (ICa) reactivation during prolonged
AP plateaus (Zaugg & Buser, 2001; Bers, 2002a,b, 2008;
Roden, 2003; Laurita & Katra, 2005) and DADs may
follow spontaneous release of intracellularly stored SR
Ca2+, leading to cytosolic Ca2+ waves and oscillationsand
increasedNCXactivity(Kass&Tsien,1982;Orchardetal.
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1983;Sternetal.1983;Wieretal.1983;Marbanetal.1986;
January et al. 1988).
The alternans that involved APD parallel similar
phenomena in clinical situations, in which such beat-
to-beat ﬂuctuations in the electrocardiographic T-
wave are thought to be a strong diagnostic precursor
of ventricular tachycardias and ventricular ﬁbrillation,
potentially leading to sudden cardiac death (Lee et al.
1987, 1988; Bloomﬁeld et al. 2006). They have also
been observed and related to arrhythmogenic tendency
in hypokalaemic murine models at high heart rates
(short baseline cycle lengths; Sabir et al. 2008b). Previous
studieshadattributedalternanstoﬂuctuationsincytosolic
SR Ca2+ that might result from digitalis toxicity and
catecholaminergic polymorphic ventricular tachycardia
(Kass & Tsien, 1982; Marks et al. 2002; Bers, 2008; Sabir
et al. 2008a).
The subsequent experiments in intact hearts
accordingly proceeded to explore the effects of
pretreatments using three different pharmacological
agents,thediydropyridinenifedipine,thebenzothiazipine
diltiazem and the indole tetramic acid CPA on
arrhythmogenic tendency induced by subsequent
introduction of FPL (Saumarez & Grace, 2000; Saumarez
et al. 2003). Nifedipine and diltiazem are L-type Ca2+
channel blockers, with diltiazem additionally inhibiting
calcium leak through RyR2s. Previous experiments using
PES protocols showed that both these agents block
triggered VT induced by either caffeine or isoproterenol
(Balasubramaniam et al. 2003, 2004). In contrast, CPA is
a potent and speciﬁc inhibitor of SERCA-mediated Ca2+
uptake (Goeger et al. 1988; Mason et al. 1989) without
affecting Ca2+ sensitivity of the contractile apparatus
(Takahashi et al. 1995), Ca2+ currents (Bonnet et al. 1994;
Badaoui et al. 1995) and the NCX (Yard et al. 1994). It has
b e e nu s e dt oi n v e s t i g a t et h er o l eo fS E R C Ai nr e g u l a t i n g
the relationship between contraction, intracellular Ca2+
transientsandforce–frequencyrelationships(Goegeretal.
1988;Masonetal.1989;Baudetetal.1993;Schwingeretal.
1997).
These experiments demonstrated that these effects of
FPLcouldbeattributedtoitsenhancingextracellularCa2+
entry; FPL-induced arrhythmogenesis was abolished in
hearts subjected to pretreatment with either nifedipine or
diltiazem.Theeffectswerealsodependentuponthedegree
of ﬁlling of the SR Ca2+ store, and accordingly abolished
by CPA. Furthermore, none of these agents, whether in
the presence or absence of FPL, altered APD values, in
contrast with earlier reports of the actions of such agents
in LQT3 (Killeen et al. 2007a; Thomas et al. 2007a).
In contrast, these arrhythmic effects correlated with
alterations in Ca2+ homeostasis at the single-cell level.
These experiments investigated the effects of FPL, as
well as nifedipine, diltiazem and CPA, upon regularly
stimulated ﬂuo−3 loaded myocytes subjected to similar
pharmacological manoeuvres to those used in the whole
hearts. Thus, FPL alone resulted in an immediate increase
in peak evoked F/F0 as well as an onset of diastolic
Ca2+ transients in isolated myocytes subjected to regular
stimulation.ThischangewasdependentuponaCa2+entry
enhanced by FPL. Thus, both nifedipine and diltiazem
reduced such transients, whose amplitude was then not
restored by a subsequent administration of FPL; in
such conditions, diastolic Ca2+ transients were absent.
Similarly,myocytespretreatedwithCPAhadreducedpeak
F/F0 transients. These were not restored by a subsequent
addition of FPL. Nevertheless, addition of FPL resulted
in an appearance of diastolic transients whose amplitude
was substantially lower than diastolic transients observed
with FPL alone. This is as expected for an action of FPL in
activating cardiac RyR2 either by Ca2+ entry or through
a direct effect reported earlier (Wasserstrom et al. 2002;
McDonough et al. 2005).
The present ﬁndings are thus compatible with a major
roleforextracellularCa2+ entryinthisarrhythmogenecity
that is attributable to a gradually developing intracellular
calcium overload.
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